Monthly
US$200
Billed every month
Erythromycin Lactobionate for Injection(注射用乳糖酸红霉素)
Companies, stages and changes, with each record available on this page.
Last 90 days: No longer listed under review: 2 applicationsSupplement delivery: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders4View records ↓
Under-review filings13View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers30View records ↓
API companies with A status4View records ↓
Chemical-drug catalogue
Loaded records: 4 holders; 1 in the quality-and-efficacy consistency-evaluation category, and 3 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 广东粤和泽药物研究有限公司 | 广东星昊药业有限公司 | 国药准字H20265708 | 2026/08/25 | 按红霉素计0.5g（50万单位） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南广升誉制药有限公司 | 海南灵康制药有限公司 | 国药准字H20265577 | 2026/08/04 | 按红霉素计0.25g（25万单位） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南广升誉制药有限公司 | 海南灵康制药有限公司 | 国药准字H20265578 | 2026/08/04 | 按红霉素计0.5g（50万单位） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广东万泰科创药业有限公司 | 广东隆赋药业股份有限公司 | 国药准字H20263149 | 2026/01/20 | 按红霉素计0.5g（50万单位） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南科伦制药有限公司 | 湖南科伦制药有限公司 | 国药准字H43020028 | 2026/10/16 | 按红霉素计0.25g（25万单位） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 湖南科伦制药有限公司 | 湖南科伦制药有限公司 | 国药准字H20269253 | 2026/10/16 | 按红霉素计0.5g（50万单位） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 30 distinct approval numbers and 18 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 上海上药新亚药业有限公司 | 国药准字H31021503 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010100792 | NHSA |
| 美罗药业股份有限公司 | 国药准字H21021678 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010101122 | NHSA |
| 武汉久安药业有限公司 | 国药准字H42020871 | 0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010101949 | NHSA |
| 成都第一制药有限公司 | 国药准字H51023236 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010102080 | NHSA |
| 西安利君制药有限责任公司 | 国药准字H61022363 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010102503 | NHSA |
| 湖北美林药业有限公司 | 国药准字H14020379 | 0.3g(30万单位) | Category A (甲) | XJ01FAH016B001010102946 | NHSA |
| 山西双雁药业有限公司 | 国药准字H14020729 | 0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010102954 | NHSA |
| 哈药集团制药总厂 | 国药准字H23021442 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B001010103712 | NHSA |
| 湖南科伦制药有限公司 | 国药准字H43020028 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010105006 | NHSA |
| 广西梧州制药(集团)股份有限公司 | 国药准字H45021339 | 0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010105156 | NHSA |
| 江西赣南海欣药业股份有限公司 | 国药准字H36021156 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010105283 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20265578 | 按红霉素计0.5g(50万单位) | Category A (甲) | XJ01FAH016B001010181251 | NHSA |
| 广东金城金素制药有限公司 | 国药准字H20263854 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010181979 | NHSA |
| 广东万泰元科创药业有限公司 | 国药准字H20263149 | 按红霉素计0.5g(50万单位) | Category A (甲) | XJ01FAH016B001010185190 | NHSA |
| 武汉久安药业有限公司 | 国药准字H42020871 | 0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010201949 | NHSA |
| 西安利君制药有限责任公司 | 国药准字H61022363 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010202503 | NHSA |
| 湖北美林药业有限公司 | 国药准字H14020379 | 0.3g(30万单位) | Category A (甲) | XJ01FAH016B001010202946 | NHSA |
| 国药集团国瑞药业有限公司 | 国药准字H34023638 | 0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010204383 | NHSA |
| 江西赣南海欣药业股份有限公司 | 国药准字H36021156 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010205283 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20265578 | 按红霉素计0.5g(50万单位) | Category A (甲) | XJ01FAH016B001010281251 | NHSA |
| 广东万泰元科创药业有限公司 | 国药准字H20263149 | 按红霉素计0.5g(50万单位) | Category A (甲) | XJ01FAH016B001010285190 | NHSA |
| 西安利君制药有限责任公司 | 国药准字H61022363 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001010302503 | NHSA |
| 美罗药业股份有限公司 | 国药准字H21021679 | 按红霉素计0.30g(30万单位) | Category A (甲) | XJ01FAH016B001020101122 | NHSA |
| 武汉久安药业有限公司 | 国药准字H42020872 | 0.3g(30万单位) | Category A (甲) | XJ01FAH016B001020101949 | NHSA |
| 西安利君制药有限责任公司 | 国药准字H61022364 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B001020102503 | NHSA |
| 山西双雁药业有限公司 | 国药准字H14022626 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B001020102954 | NHSA |
| 国药集团国瑞药业有限公司 | 国药准字H34023637 | 0.3g(30万单位) | Category A (甲) | XJ01FAH016B001020104383 | NHSA |
| 湖南科伦制药有限公司 | 国药准字H43020027 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B001020105006 | NHSA |
| 广西梧州制药(集团)股份有限公司 | 国药准字H45021338 | 0.3g(30万单位) | Category A (甲) | XJ01FAH016B001020105156 | NHSA |
| 江西赣南海欣药业股份有限公司 | 国药准字H36021155 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B001020105283 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20265577 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001020181251 | NHSA |
| 广东金城金素制药有限公司 | 国药准字H20263855 | 按红霉素计0.5g(50万单位) | Category A (甲) | XJ01FAH016B001020181979 | NHSA |
| 武汉久安药业有限公司 | 国药准字H42020872 | 0.3g(30万单位) | Category A (甲) | XJ01FAH016B001020201949 | NHSA |
| 湖南科伦制药有限公司 | 国药准字H43020027 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B001020205006 | NHSA |
| 海南广升誉制药有限公司 | 国药准字H20265577 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001020281251 | NHSA |
| 美罗药业股份有限公司 | 国药准字H21021678 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001030101122 | NHSA |
| 西安利君制药有限责任公司 | 国药准字H61022364 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B001030102503 | NHSA |
| 国药集团国瑞药业有限公司 | 国药准字H34023638 | 0.25g(25万单位) | Category A (甲) | XJ01FAH016B001030104383 | NHSA |
| 湖南科伦制药有限公司 | 国药准字H43020028 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001030105006 | NHSA |
| 江西赣南海欣药业股份有限公司 | 国药准字H36021155 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B001030105283 | NHSA |
| 西安利君制药有限责任公司 | 国药准字H61022364 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B001030202503 | NHSA |
| 美罗药业股份有限公司 | 国药准字H21021679 | 按红霉素计0.30g(30万单位) | Category A (甲) | XJ01FAH016B001040101122 | NHSA |
| 西安利君制药有限责任公司 | 国药准字H61022364 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B001040102503 | NHSA |
| 西安利君制药有限责任公司 | 国药准字H61022363 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B001050102503 | NHSA |
| 成都第一制药有限公司 | 国药准字H51023235 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B003010102080 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20053846 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B013010104152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20053846 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B013010204152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20053847 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B013020104152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20053847 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B013020204152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20053846 | 按红霉素计0.25g(25万单位) | Category A (甲) | XJ01FAH016B013030104152 | NHSA |
| 瑞阳制药股份有限公司 | 国药准字H20053847 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B013040104152 | NHSA |
| 西安迪赛生物药业有限责任公司 | 国药准字H61021775 | 按红霉素计0.3g(30万单位) | Category A (甲) | XJ01FAH016B014010102470 | NHSA |
| 广东粤和泽药物研究有限公司 | 国药准字H20265708 | 按红霉素计0.5g(50万单位) | Category A (甲) | XJ01FAH016B001010184887 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 13 filings and 8 distinct first applicants.
Generic 11 · Supplement 2
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 苏州二叶制药有限公司 | CYHS2504472 | Generic | 2025/12/30 | Not stated by source | CDE |
| 苏州二叶制药有限公司 | CYHS2504471 | Generic | 2025/12/30 | Not stated by source | CDE |
| 广东大翔制药有限公司;海南通用三洋药业有限公司 | CYHS2601857 | Generic | 2026/08/03 | Not stated by source | CDE |
| 苏州朗科生物技术股份有限公司;江苏海岸药业有限公司 | CYHS2502490 | Generic | 2025/07/12 | Not stated by source | CDE |
| 苏州朗科生物技术股份有限公司;江苏海岸药业有限公司 | CYHS2502489 | Generic | 2025/07/12 | Not stated by source | CDE |
| 海韬新药研发（江苏）有限公司;津药和平（天津）制药有限公司 | CYHS2500734 | Generic | 2025/02/13 | Not stated by source | CDE |
| 江西赣南海欣药业股份有限公司 | CYHB2650137 | Supplement | 2026/06/16 | Not stated by source | CDE |
| 江西赣南海欣药业股份有限公司 | CYHB2650136 | Supplement | 2026/06/16 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2600795 | Generic | 2026/04/08 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2600794 | Generic | 2026/04/08 | Not stated by source | CDE |
| 福安药业集团湖北人民制药有限公司 | CYHS2503278 | Generic | 2025/09/05 | Not stated by source | CDE |
| 福安药业集团湖北人民制药有限公司 | CYHS2503277 | Generic | 2025/09/05 | Not stated by source | CDE |
| 海南允鼎医药科技有限公司;海口奇力制药股份有限公司 | CYHS2502675 | Generic | 2025/07/24 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 广东大翔制药有限公司;海南通用三洋药业有限公司 | CYHS2601857 | Generic | 2026/08/03 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2600795 | Generic | 2026/04/08 | Not stated by source | CDE |
| 哈尔滨三联药业股份有限公司 | CYHS2600794 | Generic | 2026/04/08 | Not stated by source | CDE |
API registrations
Non-component matches: 4 companies with A status and 4 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 乳糖酸红霉素 | 成都百裕制药股份有限公司 | Y20260000044 | I | Exact ingredient | 2026/01/30 | CDE |
| 乳糖酸红霉素 | 江西赣南海欣药业股份有限公司 | Y20250001359 | I | Exact ingredient | 2025/12/25 | CDE |
| 乳糖酸红霉素 | 浙江华纳药业有限公司 | Y20250000445 | I | Exact ingredient | 2025/06/06 | CDE |
| 乳糖酸红霉素 | 广东态森德制药有限公司 | Y20240001069 | I | Exact ingredient | 2024/12/02 | CDE |
| 乳糖酸红霉素 | 北京金城泰尔制药有限公司 | Y20230001264 | A | Exact ingredient | 2025/10/23 | CDE |
| 乳糖酸红霉素 | 西安利君制药有限责任公司 | Y20190005670 | A | Exact ingredient | 2026/01/07 | CDE |
| 乳糖酸红霉素 | 黄石黄抗药业有限公司 | Y20190004886 | A | Exact ingredient | — | CDE |
| 乳糖酸红霉素 | 美罗药业股份有限公司 | Y20190004202 | A | Exact ingredient | 2025/01/16 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/07No longer listed under review
广东态森德制药有限公司;广东星昊药业有限公司
CYHS2404422
Fact date: 2026/11/07 · Site observation date: 2026/11/07
Accepted: 2024/12/20
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/07No longer listed under review
广州艾奇西新药研究有限公司;成都通德药业有限公司
CYHS2404313
Fact date: 2026/11/07 · Site observation date: 2026/11/07
Accepted: 2024/12/12
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/16Supplement delivery
湖南科伦制药有限公司
CYHB2550288 · 国药准字H20269253
Fact date: 2026/10/16 · Publication date: 2026/10/21 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 3 ↗ -
2026/10/16Supplement delivery
湖南科伦制药有限公司
CYHB2550287
Fact date: 2026/10/16 · Publication date: 2026/10/21 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 2 ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Erythromycin Lactobionate for Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy